

Statement letter for prematurely termination of clinical trial

Full title of the trial:

Effect of treatment with Semaglutide on cognitive function,
neuroinflammation and hepatic nitrogen metabolism in patients with nonalcoholic
steatohepatitis: A randomized placebo-controlled trial

EudraCT number:

2020-004373-50

Sponsor's protocol code number:

369852

Date of termination:

26th of March 2023

Sponsor of the trial:

Karen Louise Thomsen

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark


Palle Juul-Jensens Boulevard 99, C117, 8200 Aarhus N, Denmark

Reason for prematurely termination:

The clinical trial was never initiated and ended before the inclusion of the first patient. The reason was failure to obtain the study drug. The manufacturer of the study drug, Novo Nordisk A/S, terminated a prior agreement with the Sponsor to supply the drug due to limited production/delivery capacity.

Sincerely,

Karen Louise Thomsen

 25/02/25